ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

TLSI vs BDSX // PIOTROSKI F-SCORE QUALITY

TriSalus Life Sciences Inc. (NASDAQ) VS. Biodesix Inc. (NASDAQ) • 15-METRIC TALLY: TLSI 2 — BDSX 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TLSI VS. BDSX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC TLSI BDSX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 84.60% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -7.96% -9.02% +1.06 TLSI /fcf-yield <GO>
Operating Margin -59.70% -31.50% -28.20 BDSX /operating-margins <GO>
Net Profit Margin -60.00% -39.90% -20.10 BDSX /net-margins <GO>
Revenue Growth (YoY) 53.40% 24.10% +29.30 TLSI /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality ACTIVE 4/9 4/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 40.5 44.0 -3.46 BDSX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $237.7M $260.8M -$23.1M BDSX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR TLSI REV BDSX REV TLSI GROSS % BDSX GROSS % TLSI FCF BDSX FCF
FY 2025 $45.2M $88.5M 84.6% — -$18.9M -$23.5M
FY 2024 $29.4M $71.3M 86.1% — -$41.2M -$51.9M
FY 2023 $18.5M $49.1M — — -$50.6M -$22.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TLSI // BETA —
BDSX // BETA —